A Randomized, Double-blind, Placebo-controlled, Phase 2a Crossover Study to Evaluate the Effect of the TRPV4 Channel Blocker, GSK2798745, on Pulmonary Gas Transfer and Respiration in Patients With Congestive Heart Failure

Trial Profile

A Randomized, Double-blind, Placebo-controlled, Phase 2a Crossover Study to Evaluate the Effect of the TRPV4 Channel Blocker, GSK2798745, on Pulmonary Gas Transfer and Respiration in Patients With Congestive Heart Failure

Completed
Phase of Trial: Phase II

Latest Information Update: 31 Aug 2017

At a glance

  • Drugs GSK 2798745 (Primary)
  • Indications Heart failure
  • Focus Therapeutic Use
  • Sponsors GlaxoSmithKline
  • Most Recent Events

    • 28 Aug 2017 Status changed from active, no longer recruiting to completed.
    • 15 Aug 2017 Planned End Date changed from 11 Aug 2017 to 21 Aug 2017.
    • 15 Aug 2017 Planned primary completion date changed from 11 Aug 2017 to 21 Aug 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top